James Brian Windsor bought 25,000 shares of RNTX at $1.00 on 2026-04-30; stock now -56.0% from 52-week high at $0.96.
James Brian Windsor purchased 25,000 shares of Rein Therapeutics at $1.00, increasing his non-derivative holdings by +1221.9% from 2,046 to 27,046 shares, while retaining 150,000 shares in stock options. The company carries negative fundamentals: $-5.8M net income in its most recent full fiscal year and $0.00 revenue in the latest quarter, against a market cap of $82.1M. The stock has declined -56.0% from its 52-week high of $2.18 and -17.2% over the past 30 days. While Windsor's cross-ticker track record shows 4 prior buys with a 90d win rate of 50.00% and average 90d return of +47.6%, the current share price of $0.96 remains well below his $1.00 purchase price. The transaction reflects a substantial increase in direct equity stake despite the company's unprofitable status and the stock's recent weakness.
ALRN CEO Windsor purchased 400 shares across 2 transactions on 2024-12-05 for blended avg $2.24, marking repeat buying at deeply depressed valuations.
James Brian Windsor, President and CEO, executed 2 separate purchases totaling 400 shares for $897.61 on 2024-12-05 at $2.24–$2.25 per share. The current price of $2.12 reflects a -69.4% decline from the 52-week high of $6.93 and a -44.2% 30-day decline. This is Windsor's third open-market buy at ALRN: prior purchases on 2023-11-20 and 2023-12-15 generated 90-day returns of +138.4% and +64.1% respectively, establishing a pattern of well-timed accumulation at this ticker. Against this backdrop, Windsor's decision to purchase at current levels—near the 52-week low of $1.65—follows his demonstrated track record of open-market buying. The company remains unprofitable with negative quarterly and full-year net income, and its fundamentals offer limited conventional rationale for the purchase. The near-term price action (stock down -44.2% in 30 days) and the CEO's repeat pattern of open-market acquisition merit investor attention.
